利索-全球专利检索

  1. 登录
  2. 注册
发明授权
CN101732332B 20(S)-人参皂苷Rg3作为制备治疗非小细胞肺癌的药物中的应用 失效 - 权利终止

20(S)-人参皂苷Rg3作为制备治疗非小细胞肺癌的药物中的应用
摘要：
本发明涉及的是一种20(S)-人参皂苷Rg3的药物应用，具体地，本发明涉及的是20(S)-人参皂苷Rg3作为制备治疗人非小细胞肺癌的药物中的应用。本发明选用人非小细胞肺癌细胞株(A549肺腺癌、H460大细胞肺癌及LTEP-78肺鳞癌)接种于裸鼠皮下，观察了SPG-Rg3对非小细胞肺癌的影响；并取肿瘤组织进行CD34免疫组织化学染色及TUNEL免疫荧光染色，观察SPG-Rg3对肿瘤血管生成及对细胞凋亡的影响；结论是20(S)-人参皂苷Rg3能明显抑制非小细胞肺癌的生长，其作用机制与其促进肿瘤细胞凋亡及抑制肿瘤血管生成有关，与环磷酰胺联合应用的协同作用不明显，可用于临床非小细胞肺癌的化学治疗。
摘要（英）：

The invention relates to medicine application of 20(S)-ginsenoside Rg3, in particular to application of 20(S)-ginsenoside Rg3 in preparation of medicines for treating a non-small cell lung cancer. In the invention, selecting a human non-small cell lung cancer cell strain (A549 lung adenocarcinoma, H460 large cell lung cancer and LTEP-78 lung squamous carcinoma) to be inoculated under the skin of a naked mouse, and observing the influence of the SPG-Rg3 on the non-small cell lung cancer; and carrying out CD34 immunohistochemistry staining and TUNEL immunofluorescence staining on tumor tissues,and observing the influence of the SPG-Rg3 on tumor angiogenesis and apoptosis. The inclusion proves that the 20(S)-ginsenoside Rg3 can remarkably inhibit the growth of the non-small cell lung cancer, has the action mechanism related with the promotion of the tumor apoptosis and the inhibition of the tumor angiogenesis and unobvious cooperation action when being combined with cyclophosphamide forapplication, and can be used for the clinical chemotherapy of the non-small cell lung cancer.

公开/授权文献
0/0